IL150490A - Process for the production of a preparation digested in the intestine containing arachidonic acid and / or docosahexaenoic acid in the form of phospholipids and a preparation obtained by it - Google Patents

Process for the production of a preparation digested in the intestine containing arachidonic acid and / or docosahexaenoic acid in the form of phospholipids and a preparation obtained by it

Info

Publication number
IL150490A
IL150490A IL150490A IL15049002A IL150490A IL 150490 A IL150490 A IL 150490A IL 150490 A IL150490 A IL 150490A IL 15049002 A IL15049002 A IL 15049002A IL 150490 A IL150490 A IL 150490A
Authority
IL
Israel
Prior art keywords
formula
egg
acid
phospholipids
enteral
Prior art date
Application number
IL150490A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Tennessee Res Foundation
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/003235 external-priority patent/WO1998036745A2/en
Application filed by Univ Tennessee Res Foundation, Abbott Lab filed Critical Univ Tennessee Res Foundation
Publication of IL150490A publication Critical patent/IL150490A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL150490A 1997-02-21 2002-06-30 Process for the production of a preparation digested in the intestine containing arachidonic acid and / or docosahexaenoic acid in the form of phospholipids and a preparation obtained by it IL150490A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number Publication Date
IL150490A true IL150490A (en) 2007-05-15

Family

ID=27122714

Family Applications (1)

Application Number Title Priority Date Filing Date
IL150490A IL150490A (en) 1997-02-21 2002-06-30 Process for the production of a preparation digested in the intestine containing arachidonic acid and / or docosahexaenoic acid in the form of phospholipids and a preparation obtained by it

Country Status (5)

Country Link
US (1) US6080787A (cg-RX-API-DMAC7.html)
JP (1) JP2011137015A (cg-RX-API-DMAC7.html)
KR (1) KR100439166B1 (cg-RX-API-DMAC7.html)
AR (1) AR011160A1 (cg-RX-API-DMAC7.html)
IL (1) IL150490A (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F
EP1372641A4 (en) * 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
EP1392278A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPIDREICH FRACTION WITH STEARIDONIC ACID AND GAMMA LINOLIC ACID FROM PLANT SEEDS AND MICROBES
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040013787A1 (en) * 2002-06-28 2004-01-22 Theuer Richard C. Fat compositions for infant formula and methods therefor
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
DK1589834T3 (da) * 2003-02-05 2007-06-18 Nutricia Nv Enteral komposition til forebyggelse og/eller behandling af sepsis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
KR20060030860A (ko) * 2003-06-24 2006-04-11 유니버시티 오브 캔사스 메디컬 센터 유아 조제유
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
KR101578498B1 (ko) * 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
WO2008147562A2 (en) * 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
CN101801200B (zh) * 2007-09-17 2014-10-29 康奈尔大学 用于预防或治疗胃肠病症的支链脂肪酸
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MX388089B (es) 2010-12-31 2025-03-19 Abbott Lab Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
EP2658400A2 (en) 2010-12-31 2013-11-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
DK2658399T4 (da) 2010-12-31 2024-03-25 Abbott Lab Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
NZ611807A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016929A2 (pt) 2010-12-31 2019-09-24 Abbott Lab oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
ES2804258T3 (es) 2010-12-31 2021-02-05 Abbott Lab Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014078544A1 (en) * 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
MX2015007935A (es) 2012-12-18 2015-10-09 Abbott Lab Fortificador de leche humana liquido concentrado que contiene proteina hipoalergenica y luteina.
WO2017117121A1 (en) * 2015-12-28 2017-07-06 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374914D1 (en) * 1982-04-12 1988-01-28 Univ Texas Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) * 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) * 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1992012711A1 (en) * 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DK0784437T3 (da) * 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) * 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids

Also Published As

Publication number Publication date
KR100439166B1 (ko) 2004-07-07
US6080787A (en) 2000-06-27
JP2011137015A (ja) 2011-07-14
KR20000075539A (ko) 2000-12-15
AR011160A1 (es) 2000-08-02

Similar Documents

Publication Publication Date Title
US6080787A (en) Methods for reducing the incidence of necrotizing enterocolitis
CA2281706C (en) Methods and compositions for reducing the incidence of necrotizing enterocolitis
US6036992A (en) Process of making an enteral formula containing long-chain polyunsaturated fatty acids
AU613420B2 (en) Dietary supplement utilizing omega-3/medium chain triglyceride mixtures
US9386794B2 (en) Nutritional composition to promote healthy development and growth
US8975299B2 (en) Lipid mixture for infant nutrition
KR101424822B1 (ko) 장쇄 다중불포화 지방산을 함유하는 영양 보충물
JP3559039B2 (ja) 炎症性疾患の治療のための非経口的に投与される医薬を調製するためのエマルジョンの使用
Martinez Docosahexaenoic acid therapy in docosahexaenoic acid‐deficient patients with disorders of peroxisomal biogenesis
JPH0811048B2 (ja) 肺疾患患者用栄養製品
JPS61502816A (ja) ダイエット補足材及びダイエットにより感染作用を最小にさせる方法
WO2014060847A1 (en) Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
TW202042800A (zh) 包含ω脂肪酸的醫藥組合物及包含彼之輸液製劑
JPH07508720A (ja) 異化代謝の病気の影響を最小限にするための食餌療法用補給物としてのモノ不飽和脂肪
CN115104731B (zh) 营养组合物以及包含所述营养组合物的食品
HK1034033B (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
CN115191604A (zh) 一种营养组合物和包含营养组合物的食品及应用
MXPA99007737A (en) Use of polyunsaturated fatty acids forreducing the incidence of necrotizing enterocolitis
WO2002015718A1 (en) Manufactured lipid emulsion having an improved balanced dietary source of vitamin f
UA66354C2 (en) Methods and compositions for reducing incidence of necrotizing enterocolitis
CZ296899A3 (cs) Přípravky pro omezení výskytu nekrotizující enterokolitidy a způsob jejich výroby
JP4307475B2 (ja) 乳幼児用栄養組成物

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees